DE60034778D1 - Stoppen, schützen und konservieren von organen - Google Patents

Stoppen, schützen und konservieren von organen

Info

Publication number
DE60034778D1
DE60034778D1 DE60034778T DE60034778T DE60034778D1 DE 60034778 D1 DE60034778 D1 DE 60034778D1 DE 60034778 T DE60034778 T DE 60034778T DE 60034778 T DE60034778 T DE 60034778T DE 60034778 D1 DE60034778 D1 DE 60034778D1
Authority
DE
Germany
Prior art keywords
protect
stop
agonist
preserve organs
effective amounts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60034778T
Other languages
English (en)
Other versions
DE60034778T2 (de
Inventor
Geoffrey Phillip Dobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hibernation Therapeutics Ltd
Original Assignee
Hibernation Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP9414A external-priority patent/AUPP941499A0/en
Priority claimed from AUPQ4199A external-priority patent/AUPQ419999A0/en
Application filed by Hibernation Therapeutics Ltd filed Critical Hibernation Therapeutics Ltd
Publication of DE60034778D1 publication Critical patent/DE60034778D1/de
Application granted granted Critical
Publication of DE60034778T2 publication Critical patent/DE60034778T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331Preservative, buffer, anticoagulant or diluent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Packages (AREA)
  • Saccharide Compounds (AREA)
  • Processing Of Solid Wastes (AREA)
  • Materials For Medical Uses (AREA)
DE60034778T 1999-03-23 2000-03-22 Stoppen, schützen und konservieren von organen Expired - Lifetime DE60034778T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPP9414A AUPP941499A0 (en) 1999-03-23 1999-03-23 Organ arrest, protection and preservation
AUPP941499 1999-03-23
AUPQ419999 1999-11-23
AUPQ4199A AUPQ419999A0 (en) 1999-11-23 1999-11-23 Organ arrest, protection and preservation
PCT/AU2000/000226 WO2000056145A1 (en) 1999-03-23 2000-03-22 Organ arrest, protection and preservation

Publications (2)

Publication Number Publication Date
DE60034778D1 true DE60034778D1 (de) 2007-06-21
DE60034778T2 DE60034778T2 (de) 2008-01-31

Family

ID=25646014

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60034778T Expired - Lifetime DE60034778T2 (de) 1999-03-23 2000-03-22 Stoppen, schützen und konservieren von organen

Country Status (18)

Country Link
US (7) US6955814B1 (de)
EP (3) EP1168912B1 (de)
JP (1) JP4949558B2 (de)
KR (1) KR20020001797A (de)
CN (1) CN1344135A (de)
AT (1) ATE361667T1 (de)
BR (1) BR0010653A (de)
CA (1) CA2364687C (de)
DE (1) DE60034778T2 (de)
ES (1) ES2287001T3 (de)
HK (1) HK1161035A1 (de)
IL (1) IL145552A0 (de)
MX (1) MXPA01009552A (de)
NO (2) NO331669B1 (de)
NZ (1) NZ514515A (de)
PL (1) PL351484A1 (de)
TR (1) TR200103235T2 (de)
WO (1) WO2000056145A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020001797A (ko) * 1999-03-23 2002-01-09 제임스 쿡 유니버시티 신체 기관의 정지, 보호 및 보존
JP2005519928A (ja) 2002-02-04 2005-07-07 ハース,ベルナー Co放出能力を有する化合物の投与によって哺乳動物を治療する方法と、co放出能力を有する化合物ならびにその医薬組成物
AUPS312602A0 (en) * 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US20040170950A1 (en) * 2002-09-12 2004-09-02 Prien Samuel D. Organ preservation apparatus and methods
CA2551169A1 (en) * 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
AU2003291847B2 (en) * 2002-12-23 2010-12-02 Hibernation Therapeutics, A Kf Llc Organ preconditioning, arrest, protection, preservation and recovery
JP2009531367A (ja) * 2006-03-31 2009-09-03 アデノバイオ エヌ.フェー. 診断および治療のためのアデノシンおよびイノシンを組み合わせて使用する組成物、方法およびキット
CN104107431A (zh) * 2006-05-29 2014-10-22 低温药理有限公司 改善的组织维持
EP2659773A1 (de) * 2006-05-29 2013-11-06 Hibernation Therapeutics Limited Verbesserte Gewebeerhaltung
US7811549B2 (en) * 2006-07-05 2010-10-12 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
CA2692256C (en) * 2006-07-25 2017-01-10 Hibernation Therapeutics Limited Trauma therapy
WO2008106724A1 (en) 2007-03-02 2008-09-12 Hibernation Therapeutics Limited Transplants
US20080269109A1 (en) * 2007-04-30 2008-10-30 Becker Lance B System and method of resuscitation of a mammal
CN101808509A (zh) * 2007-07-25 2010-08-18 低温药理有限公司 改进的器官保护、维护和康复
DE102007035642A1 (de) * 2007-07-30 2009-02-12 Grietje Beck Substanzen zur Protektion von Zellen und Geweben gegen Schädigung durch ungünstige Bedingungen
WO2009092516A2 (en) * 2008-01-22 2009-07-30 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
US20120046354A1 (en) * 2010-08-18 2012-02-23 Ehrenpreis Eli D Anti-oxidant lozenges for the prevention and treatment of radiation induced mucositis, precancerous lesions, oral cancer and other oral cavity mucosal disorders
JP5978291B2 (ja) 2011-04-19 2016-08-24 アルファーマ インコーポレイテッドAlfama,Inc. 一酸化炭素放出分子およびその使用
EP2734235B1 (de) 2011-07-21 2017-03-22 Alfama, Inc. Kohlenmonoxidfreisetzende rutheniummoleküle und ihre verwendungen
US9381245B2 (en) 2012-10-19 2016-07-05 New York University Methods for inhibiting osteolysis
CN105705151A (zh) 2013-07-17 2016-06-22 低温药理Kf有限公司 一种用于治疗出血、休克和脑损伤的方法
JP2013234200A (ja) * 2013-08-19 2013-11-21 Hibernation Therapeutics Ltd 組織維持の改善
US10092591B2 (en) 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
CN103893205B (zh) * 2014-04-15 2016-03-09 青岛大学附属医院 一种包含利多卡因和腺苷的心脏停搏液及其制备方法
US20170049811A1 (en) * 2014-05-01 2017-02-23 Catherine E. Berry Modified single dose, microplegic approach to cardioplegia for adult heart
US9501418B2 (en) * 2014-06-26 2016-11-22 HGST Netherlands B.V. Invalidation data area for cache
CN109769797A (zh) * 2017-11-13 2019-05-21 合肥华琪生物工程有限公司 一种器官保存液

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU878297A1 (ru) 1978-05-03 1981-11-07 Научно-Исследовательский Институт Трансплантологии И Искусственных Органов Состав дл сохранени жизнеспособности оперируемого сердца
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5006512A (en) 1987-10-02 1991-04-09 Tsuyoshi Ohnishi Therapeutic usages of inhibitors for a potassium efflux channel
US5256770A (en) * 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5145771A (en) * 1990-04-12 1992-09-08 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
US5206222A (en) 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
CN1057192A (zh) 1991-06-30 1991-12-25 汪庆富 风油精聚胺酯海绵的制备工艺
US5407793A (en) 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
RU2025973C1 (ru) 1992-02-10 1995-01-09 Научно-производственное предприятие "Биофарм" Раствор для консервации живых органов
US5370989A (en) 1992-04-03 1994-12-06 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
US5679706A (en) * 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
US5554497A (en) * 1994-12-12 1996-09-10 Charlotte-Mecklenburg Hospital Authority Cardioplegic solution for arresting an organ
US5656420A (en) * 1995-02-24 1997-08-12 University Of Kentucky Research Foundation Method for employing the delta opioid dadle to extend tissue survival time during ischemia
JP3875295B2 (ja) * 1995-11-30 2007-01-31 功 竹内 心筋保護液
WO1998009523A1 (en) 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
IT1297886B1 (it) * 1997-02-28 1999-12-20 Carmine Antropoli Nifedipina per uso topico
AU740770B2 (en) 1997-06-18 2001-11-15 Aderis Pharmaceuticals, Inc. Compositions and methods for preventing restenosis following revascularization procedures
CN1057192C (zh) 1997-09-10 2000-10-11 上海长征医院 一种配制多器官保存液的方法
US6011017A (en) 1998-04-15 2000-01-04 Cypros Pharmaceutical Corp. Method of reducing pulmonary hypertension and atrial fibrillation after surgery using cardiopulmonary bypass
PT1102589E (pt) 1998-07-16 2006-12-29 Memorial Sloan Kettering Inst Composições tópicas compreendendo um analgésico opióide e um antagonista do nmda
KR100269540B1 (ko) 1998-08-28 2000-10-16 윤종용 웨이퍼 상태에서의 칩 스케일 패키지 제조 방법
ES2435847T3 (es) 1998-10-23 2013-12-23 Polyheal Ltd. Composiciones de microesferas para curar heridas
US6358208B1 (en) 1998-11-21 2002-03-19 Philipp Lang Assessment of cardiovascular performance using ultrasound methods and devices that interrogate interstitial fluid
KR20020001797A (ko) * 1999-03-23 2002-01-09 제임스 쿡 유니버시티 신체 기관의 정지, 보호 및 보존
US6586413B2 (en) * 1999-11-05 2003-07-01 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
AU2001231189A1 (en) 2000-01-27 2001-08-07 Childrens Hospital Research Foundation Transdermal anesthetic and vasodilator composition and methods for topical administration
JP2001261575A (ja) 2000-03-13 2001-09-26 General Hospital Corp 血管収縮を調節する方法とその組成物
US6569615B1 (en) 2000-04-10 2003-05-27 The United States Of America As Represented By The Department Of Veteran's Affairs Composition and methods for tissue preservation
KR20030060771A (ko) 2000-04-28 2003-07-16 메모리얼 슬로안-케터링 캔서 센터 국소용 마취제/아편양약물 제제 및 이들의 용도
ATE332668T1 (de) 2000-09-26 2006-08-15 Medtronic Inc Medizinische vorrichtung zur blutstromsteuerung
GB0028414D0 (en) 2000-11-22 2001-01-03 Univ Leeds Flush preservation solution
WO2003063782A2 (en) 2002-01-29 2003-08-07 Cognetix, Inc. Kappa-pviia-related conotoxins as organ protectants
ES2318129T3 (es) 2002-04-18 2009-05-01 Cv Therapeutics, Inc. Procedimiento de tratamiento de arritmias quie comprende la administracion de un agonista de adenosina a1 con un betabloqueante.
AUPS312602A0 (en) 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US20040229780A1 (en) * 2002-09-20 2004-11-18 Olivera Baldomero M. KappaM-conopeptides as organ protectants
US6921633B2 (en) 2002-11-18 2005-07-26 Biolife Solutions Incorporated Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
US20040167226A1 (en) 2002-12-16 2004-08-26 Serafini Tito A. Methods for the treatment of pain and traumatic injury using benzamides and compositions containing the same
GB2436255B (en) 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
CA2551169A1 (en) 2002-12-23 2004-07-08 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
US6992075B2 (en) 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
CA2561452A1 (en) 2003-06-02 2004-12-16 Samaritan Pharmaceuticals, Inc. Neuroprotective benzoate and benzamide compounds
US7049309B2 (en) * 2003-10-14 2006-05-23 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one potassium channel modulators
JP2008525468A (ja) 2004-12-22 2008-07-17 エモリー・ユニバーシティ ポストコンディショニング臓器保護作用を増強する治療補助薬
US20070009880A1 (en) 2005-07-11 2007-01-11 Toledo Luis H Methods And Solutions For Storing Donor Organs
EP2659773A1 (de) 2006-05-29 2013-11-06 Hibernation Therapeutics Limited Verbesserte Gewebeerhaltung
CA2692256C (en) 2006-07-25 2017-01-10 Hibernation Therapeutics Limited Trauma therapy
WO2008106724A1 (en) 2007-03-02 2008-09-12 Hibernation Therapeutics Limited Transplants
CN100423638C (zh) 2007-03-22 2008-10-08 南京吉脉生物技术有限公司 一种器官保存液及其制备方法
CN101808509A (zh) 2007-07-25 2010-08-18 低温药理有限公司 改进的器官保护、维护和康复

Also Published As

Publication number Publication date
PL351484A1 (en) 2003-04-22
IL145552A0 (en) 2002-06-30
NO20014557D0 (no) 2001-09-19
US20090298789A1 (en) 2009-12-03
EP2359688B1 (de) 2015-05-27
US20070270372A1 (en) 2007-11-22
EP1168912A1 (de) 2002-01-09
US20160263141A1 (en) 2016-09-15
EP1790223A1 (de) 2007-05-30
US6955814B1 (en) 2005-10-18
WO2000056145A1 (en) 2000-09-28
US20050171050A1 (en) 2005-08-04
US7749522B2 (en) 2010-07-06
US20100298254A1 (en) 2010-11-25
TR200103235T2 (tr) 2002-01-21
KR20020001797A (ko) 2002-01-09
EP1168912B1 (de) 2007-05-09
NO331669B1 (no) 2012-02-20
CA2364687C (en) 2014-11-18
NO20110807L (no) 2001-11-07
MXPA01009552A (es) 2003-08-19
NO20014557L (no) 2001-11-07
CA2364687A1 (en) 2000-09-28
NZ514515A (en) 2003-11-28
JP2002539224A (ja) 2002-11-19
US7223413B2 (en) 2007-05-29
EP1168912A4 (de) 2002-07-31
US9320753B2 (en) 2016-04-26
BR0010653A (pt) 2002-02-05
ES2287001T3 (es) 2007-12-16
CN1344135A (zh) 2002-04-10
US20130184231A1 (en) 2013-07-18
JP4949558B2 (ja) 2012-06-13
EP2359688A1 (de) 2011-08-24
ATE361667T1 (de) 2007-06-15
DE60034778T2 (de) 2008-01-31
HK1161035A1 (en) 2012-08-24

Similar Documents

Publication Publication Date Title
DE60034778D1 (de) Stoppen, schützen und konservieren von organen
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
BR0014384A (pt) Compostos para o tratamento da isquémia
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
TR200002480T2 (tr) İzaşemi tedavisi için guanidin türevleri
ATE287707T1 (de) Injizierbare propofol-formulierungen
TR199801679T2 (xx) Osteoporoz i�in birle�tirme terapisi.
TR200101174T2 (tr) Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid.
DE69525291D1 (de) Bisphosphonat und anti-Resorption Agentien, enthaltende Zusammensetzungen zur Hemmung der Knochenschwund
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
ATE357928T1 (de) Pharmazeutische zusammensetzung für thrombinpeptidderivaten
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
BRPI0408136A (pt) derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
BR0214159A (pt) Sistema farmacêutico radiopaco de liberação prolongada
DE60124694D1 (de) Verbesserte lipidzusammensetzungen und darin enthaltene derivate des 3-methoxybenzylthioharnstoffs
BR0100954A (pt) Utilização de o-vanilina e combinações deo-vanilina/trolox(r)
DK0764023T3 (da) Forbindelser og præparater til administrering via oral inhalation eller insufflation
DK1073436T3 (da) Forbedret fremgangsmåde til udryddelse af helicobacter pylori
GB2363573A (en) Organ arrest, protection and preservation
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
NZ513603A (en) ADP-ribosylation inhibitors and remedies for endotoxic bacterial enteric infection containing proanthocyanidin as the active ingredient
ES2053679T3 (es) Embonato de azelastina, procedimiento para su preparacion y preparados farmaceuticos que contienen embonato de azelastina como principio activo.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition